Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > New competitor to Epuris launches in Canada

<< Previous

Bullboard Posts

Next >>

Post by Spuds69on Dec 04, 2023 4:29pm

468 Views

Post# 35767805

New competitor to Epuris launches in Canada

FYI - Sun Pharma Canada Launches (PR)ABSORICA LD® (isotretinoin capsules) for Treatment of Severe Acne (yahoo.com)

Unbelievable that this product has been approved since June 2023 and this was never mentioned in any CPH disclosure. Now a direct competitor is on the market and Sun has an actual sales force in Canada. They sell other derm products in Canada. Good bye to the Epuris cash cow! Sun will eat CPH's lunch if CPH continues to have no sales force to support Epuris.

Sell now as the share price won't get any higher with this news.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec